Digest Network Come funziona
Network
/
Società
Cr
Non verificato

Crinetics Pharmaceuticals, Inc.

Di cosa scriviamo

Annunci EconomiciBiotecnologiaMedicina Salute Benessere

5 comunicati stampa

Guarda tutti i comunicati
02/06/2026
Biotecnologia
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
Fonte
Crinetics Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
22/01/2026
Biotecnologia
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Fonte
Crinetics Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
11/12/2025
Biotecnologia
Medicina Salute Benessere
Annunci Economici
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Fonte
Crinetics Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
03/12/2025
Biotecnologia
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
Fonte
Crinetics Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0
25/09/2025
Biotecnologia
Medicina Salute Benessere
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
Fonte
Crinetics Pharmaceuticals, Inc.
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0